Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 7/20 | 0.44 |
| ▸ | MMP9 | P14780 | 7/20 | 0.44 |
| ▸ | MMP8 | P22894 | 4/20 | 0.44 |
| ▸ | MMP12 | P39900 | 4/20 | 0.44 |
| ▸ | MMP14 | P50281 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176234 | 0.91 | GBA1 (0.49) | GBA1NPY5RMMP2MMP9KMT2A | |
| SCHEMBL19975409 | 0.83 | GBA1 (0.51) | SMN1; SMN2GBA1NPY5RKMT2APOLB | |
| SCHEMBL19975283 | 0.79 | CCR1 (0.49) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL19974771 | 0.78 | KMT2A (0.47) | SMN1; SMN2GBA1NPY5RMMP2MMP9 | |
| SCHEMBL21176241 | 0.78 | KMT2A (0.46) | SMN1; SMN2GBA1KMT2APOLBMEN1 | |
| SCHEMBL5875648 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2MMP2MMP9MMP8MMP12 | |
| SCHEMBL5189435 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2MMP2MMP9MMP8MMP12 | |
| SCHEMBL7655438 | 0.74 | GBA1 (0.55) | GBA1MMP2MMP9MMP8MMP12 | |
| SCHEMBL19974825 | 0.73 | KMT2A (0.49) | SMN1; SMN2GBA1NPY5RKMT2APOLB | |
| SCHEMBL19975337 | 0.72 | KMT2A (0.54) | SMN1; SMN2GBA1NPY5RKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | SMN1; SMN2 706/4885GBA1 68/4885NPY5R 4477/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | SMN1; SMN2 1086/4885GBA1 81/4885NPY5R 4656/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | SMN1; SMN2 706/4885GBA1 68/4885NPY5R 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.